Extreme Movers: DeepSeek's picks for 2026-09-23
DeepSeek picked MRNA, PLTR, IONQ, BYND, JAGX for a 1-day horizon. Average directional return: +10.62%. Directions called correctly: 80%.
| Experiment | Extreme Movers |
|---|---|
| Model | DeepSeek |
| Prompt version | extreme-movers-v9 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-23 |
| Measured to | 2026-09-24 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +10.62% |
| Directions called correctly | 80% |
| Benchmark return | -0.69% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | MRNA | up | +0.51% | +0.51% | 75% | +1.20% | Yes |
| 2 | PLTR | up | +0.13% | +0.13% | 72% | +0.81% | Yes |
| 3 | IONQ | up | -0.64% | -0.64% | 70% | +0.05% | No |
| 4 | BYND | down | -3.19% | +3.19% | 68% | +3.88% | Yes |
| 5 | JAGX | down | -49.93% | +49.93% | 65% | +50.62% | Yes |
The model's market view
US equities closed mixed on September 23, 2026, with the Nasdaq hitting a record high while breadth remained extremely narrow. The source session featured violent single-stock moves driven by binary catalysts: quantum computing breakthroughs, cancer-vaccine data, activist campaigns, and micro-cap squeezes. The highest-conviction continuation setups are in names with substantive, verifiable catalysts (MRNA's ESMO abstracts, IONQ's error-correction decoder, PLTR's FAA deployment), while the most reliable reversal setups are in micro-cap names that experienced unsustainable one-day spikes (JAGX). BYND represents a continuation of a structural downtrend driven by debt-to-equity dilution and legal headwinds. The window is 1 trading session; all returns are close-to-close.
Why each pick
MRNA
Moderna closed the source session up 5.56% at $182.56, driven by the acceptance of three abstracts on its mRNA-based individualized neoantigen therapy (intismeran autogene, co-developed with Merck) for presentation at the ESMO Congress 2026. The catalyst is substantive: the abstracts signal that the Phase III melanoma data readout expected in October is on track, and the stock has already demonstrated a 176.97% single-day move in August on positive Phase III data. UBS maintains a Neutral rating with a $150 target, implying downside, but the pre-ESMO news flow typically sustains momentum for several sessions. The main risk is a sharp reversal if a large holder decides to lock in gains before the October data. Reference price is an intraday quote from September 23, 2026, sourced from cnyes.com.
PLTR
Palantir closed the source session up 1.04% at $184.99, and the catalyst is substantive: the FAA deployed Palantir's AI-based SMART flight management system at three major Washington-area airports, marking the first operational deployment of the technology in the US. Rosenblatt reiterated its Buy rating with a $225 target, noting that the FAA contract expansion could materially boost government revenues. The stock hit a fresh 2026 high above $193 intraday on September 23. Risks include a premium valuation (GF Value estimates fair value at $180.41) and the possibility that the FAA catalyst is already partially priced in after the initial 5% pop. If market breadth continues to deteriorate, high-multiple AI names could see outsized profit-taking. Reference price is an intraday quote from September 23, 2026, sourced from Morningstar.
IONQ
IonQ closed the source session up 10.78% at $45.13, after announcing the industry's first end-to-end real-time quantum error-correction decoder running on a single standard CPU, supporting up to 408 logical qubits and over 31.5 million quantum operations with as little as 0.02% execution-time overhead. The catalyst is substantive and was accompanied by an Nvidia partnership announcement and the Quantum World Congress catalyst. The stock surged over 10% in premarket and early trading, with intraday highs above $46. Risks include extreme volatility (5-year beta of 3.30), the stock trading roughly 48% below its 52-week high, and the possibility of a sharp intraday reversal given the speculative nature of quantum computing names. The narrow market breadth could amplify a sell-off in high-beta names if SPY turns negative. Reference price is an intraday quote from September 23, 2026, sourced from Robinhood.
BYND
Beyond Meat closed the source session down 11.86% at $11.51, continuing a structural downtrend driven by debt-to-equity dilution, weak Q2 financials (revenue and margin declines), a $15.44 million legal judgment, and ongoing efforts to maintain Nasdaq listing compliance through a reverse stock split. The catalyst is substantive and negative: the company's fundamental deterioration is well-documented, and the $12.50 average analyst target implies only modest upside from current levels. The risk to the downside continuation thesis is that short sellers may cover into any positive news flow, and the stock is already down significantly year-to-date. However, the lack of a near-term positive catalyst makes continued weakness the higher-probability outcome for the next session. Reference price is an intraday quote from September 23, 2026, sourced from Yahoo Finance.
JAGX
Jaguar Health closed the source session down 45.39% at $18.82, after a historic 1,190% single-day surge on Tuesday driven by FDA fee waivers for Mytesi and Canalevia-CA1 combined with aggressive retail buying. The catalyst for the reversal is substantive: the massive spike was driven by a one-time regulatory fee waiver announcement that does not change the company's underlying financial profile, and profit-taking began immediately in the following session. The stock is a micro-cap with a market cap of roughly $11.87 million and a share price below $1 on a split-adjusted basis, making it extremely volatile. The primary risk is a short squeeze that could drive the stock sharply higher, invalidating the down thesis. However, the lack of fundamental support for the prior spike makes a reversal the higher-probability outcome. Reference price is an intraday quote from September 23, 2026, sourced from Robinhood.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | MPWR, SHOP, MU, ADBE, CSCO | -0.49% | 20% |
| Claude Opus 5 | VKTX, SCHW, SNDK, PSKY, NYT | -1.69% | 60% |
| Gemini 1.5 Pro | MU, PLTR, SCHW, JPM, AMP | -0.25% | 60% |
| Grok 4.5 | MRNA, INTC, AMD, AKAM, WBD | -0.34% | 40% |
| GPT-6 | IMCC, CMPX, VKTX, GRML, MAZE | -9.71% | 20% |
Written up on ForecastNest Insights: Extreme Movers: DeepSeek's picks for 2026-09-23.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.